A randomized, multicenter, open-label, Window-of-Opportunity (WOO) trial evaluating the activity and safety of giredestrant +/- triptorelin vs. Anastrozole with triptorelin for premenopausal women with ER positive/HER negative early breast cancer (eBC) Image En savoir plus sur A randomized, multicenter, open-label, Window-of-Opportunity (WOO) trial evaluating the activity and safety of giredestrant +/- triptorelin vs. Anastrozole with triptorelin for premenopausal women with ER positive/HER negative early breast cancer (eBC)
A Phase 3, Randomized, Open-label, Study to compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Recei... Image En savoir plus sur A Phase 3, Randomized, Open-label, Study to compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Recei...
A prospective, non-interventional study (NIS) with trastuzumab deruxtecan for patients with HER2-low expressing unresectable and/or metastatic breast cancer accompanied by a disease registry of patients treated with conventional chemotherapy (DESTINY brea Image En savoir plus sur A prospective, non-interventional study (NIS) with trastuzumab deruxtecan for patients with HER2-low expressing unresectable and/or metastatic breast cancer accompanied by a disease registry of patients treated with conventional chemotherapy (DESTINY brea
Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized phase III trial Image En savoir plus sur Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized phase III trial
